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Background: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2
(VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to
disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially combines the
advantages of anti-angiogenic therapy and active immunotherapy.
Methods/Design: This phase I trial examines the safety, tolerability, and immunological and clinical responses to
VXM01. The randomized, placebo-controlled, double blind dose-escalation study includes up to 45 patients with
locally advanced and stage IV pancreatic cancer. The patients will receive four doses of VXM01 or placebo in
addition to gemcitabine as standard of care. Doses from 106 cfu up to 1010 cfu of VXM01 will be evaluated in the
study. An independent data safety monitoring board (DSMB) will be involved in the dose-escalation decisions. In
addition to safety as primary endpoint, the VXM01-specific immune reaction, as well as clinical response parameters
will be evaluated.
Discussion: The results of this study shall provide the first data regarding the safety and immunogenicity of the
oral anti-VEGFR-2 vaccine VXM01 in cancer patients. They will also define the recommended dose for phase II and
provide the basis for further clinical evaluation, which may also include additional cancer indications.
Trial registration: EudraCT No.: 2011-000222-29, NCT01486329, ISRCTN68809279
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Angiogenesis contributes to solid tumor growth and me-
tastasis [1]. Compounds like bevacizumab and others,
for example small molecules such as sunitinib and axiti-
nib that specifically target the tumor neovasculature
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distribution, and reproduction in any medium[2-4]. Tumor neovasculature is lined with endothelial
cells that are overexpressing vascular endothelial growth
factor receptor (VEGFR) 2 and are readily accessible
via the blood stream [5]. The genetic stability of those
cells and their ability to support hundreds of tumor
cells per endothelial cell make them a prime target for
anti-cancer therapy, be it via antibodies, tyrosine kinase
inhibitors, or vaccines [6].
Recently, T-cell based immunotherapy has gained
some clinical success in prostate cancer and validated
the potential of anti-cancer vaccination which was oftenntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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system against cancer cells faces multiple challenges. For
example, cancerous lesions are often polyclonal and can-
cer cells have the propensity to mutate. Antigen specific
therapy often only results in a selection of non-antigen
bearing cells. Further hurdles include tumor encapsula-
tion and loss or down-regulation of MHC molecules.
Vaccination approaches that target that the tumor neo-
vasculature should in theory overcome those hurdles.
The trial presented here attempts to combine anti-
angiogenic therapy and vaccination, targeting VEGFR-2
using a new vaccine (VXM01). Hypothetically, vaccin-
ation with VXM01 should lead to breakdown of existing
tumor vasculature and support the development of an
immune memory against proliferating endothelial cells.
In 2002, we published a preclinical study combining
anti-angiogenic therapy and vaccination for the first time
[8]. Vaccinating mice against the VEGFR-2 induced
strong resistance against a variety of different tumor
challenges such as melanoma, colon cancer, and lung
cancer, both in prophylactic as well as therapeutic ex-
perimental settings. These effects were long-lived and
mediated by cytotoxic T-cells. Surprisingly, a slight delay
in wound healing was the only toxicity that was
observed.
To our knowledge, this is the first clinical trial of an
oral cancer vaccine. In addition, this vaccine has the po-
tential to be effective against multiple tumor types.
Methods
Preclinical efficacy assessment
The efficacy and safety of this approach in animals has
been validated multiple times by us and others [8-10].
Further, own unpublished experiments showed an activ-
ity of this vaccine in two different models of pancreatic
cancer.
VXM01, the vaccine used in this trial, is a humanized
version of the anti-VEGFR-2 vaccine previously tested in
mice. It encodes the human full-length VEGFR-2 and
uses the licensed Salmonella typhi strain Ty21a instead
of Salmonella typhimurium as a carrier. The vaccine is
assumed to lead to VEGFR-2 protein expression in
monocytes and dendritic cells after entry of VXM01 in
the Peyer’s patches via M cells of the gut, and
internalization by antigen-presenting cells followed by
translation of the encoded DNA [11,12].
Preclinical safety assessment
Preclinical toxicity studies in mice included, but were
not restricted to a single dose toxicity study in mice con-
ducted with the human vaccine VXM01. As VXM01 is
specific for the human host, the study of the human vac-
cine in mice focused on possible effects of process-
related impurities and related signs and symptoms ofpossible relevance for cardiovascular, respiratory, or cen-
tral nervous system impairment. In order to investigate
the toxicity profile of an anti-VEGFR-2 T-cell response,
a repeated dose toxicity study was conducted using the
murine analog construct of VXM01 which induced a
dose-dependent T-cell response in mice. In accordance to
our previous observations, no treatment-related deaths
and no toxicologically important clinical signs were
observed throughout these studies, which were conducted
according to Good Laboratory Practice (GLP).
The vector Salmonella typhi Ty21a used here is a live,
attenuated bacterial carrier that allows for the oral deliv-
ery of the vaccine VXM01. It is itself an approved vac-
cine against typhoid fever (VivotifW, Crucell, formerly
Berna Biotech Ltd., Switzerland) that has been exten-
sively tested and has demonstrated its safety regarding
patient toxicity as well as transmission to third parties
[13,14]. VXM01 is classified as a gene transfer medicinal
product and subject to the respective guidance and regu-
lations [15].
This study has been approved by the German regula-
tory agency, the Paul-Ehrlich-Institute (PEI). In accord-
ance with the Declaration of Helsinki [16], the German
Drug Law (Arzneimittelgesetz [AMG]) [15], the German
Good Clinical Practice guideline (GCP-V) [17], and the
Note for Guidance on Good Clinical Practice (GCP)
[18], the study was presented to the responsible Ethics
Committee of the Medical Faculty of the University of
Heidelberg and the PEI. The opinion of the ethics com-
mittee and the authorization of the PEI were obtained
prior to any study-related procedures. The recruiting
study center is the Clinic of General Surgery; drug
exposure is done and patients are supervised at the
ISO-certified Clinical Research Unit (KliPS) of the
Department of Clinical Pharmacology and Pharmacoepi-
demiology, Heidelberg University Hospital, Heidelberg,
Germany. Study patients will be hospitalized for ten days
in KliPS during the sensitive administration period of
the vaccine.Study description
This is a monocenter, placebo controlled, double blind
dose escalation study of the experimental vaccine
VXM01 in patients with advanced inoperable or stage IV
pancreatic cancer. The vaccine will be given as add-on to
a standard of care gemcitabine treatment.Study objectives
The objectives are to examine the safety and tolerability,
and immunological and clinical responses to the investi-
gational anti-VEGFR-2 vaccine VXM01, as well as to
identify the maximum tolerated dose (MTD) of VXM01.
The MTD is defined as the highest dose level at which
Niethammer et al. BMC Cancer 2012, 12:361 Page 3 of 8
http://www.biomedcentral.com/1471-2407/12/361less than two of up to six patients under VXM01 treat-
ment experience a dose-limiting toxicity (DLT).
Primary endpoints for safety and tolerability are as
follows: Number of DLTs defined as any adverse event
(AE) related to study drug of grade 4 or higher, or grade
3 or higher for gastrointestinal fistula, diarrhea, gastro-
intestinal perforation, multi-organ failure, anaphylaxis,
any auto-immune disorder, cytokine-release syndrome,
intestinal bleeding, renal failure, proteinuria, thrombo-
embolic events, stroke, heart failure, or vasculitis accord-
ing to the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE) [19].
Secondary endpoints, which assess the efficacy of
the experimental vaccine to elicit a specific immune
response to VEGFR-2, include the number of immune
positive patients.
A further secondary endpoint will be the clinical re-
sponse: Tumor staging according to the response evalu-
ation criteria in solid tumors (RECIST) [20], overall
response rate, progression free survival, overall survival,
and changes in tumor perfusion. Tumor perfusion will
be determined by dynamic contrast-enhanced Magnetic
Resonance Imaging (DCE-MRI) [21] on a 1.5 Tesla
system (Magnetom Aera, Siemens, Erlangen, Germany).Investigational products
VXM01 has been manufactured according to Good
Manufacturing Practice (GMP) and is given in a buffered
solution. The placebo control consists of isotonic sodium
chloride solution.Patient selection and study design
This study will include a maximum of 45 patients with
either locally advanced and inoperable or stage IV pan-
creatic cancer. The eligibility criteria are summarized in
Table 1.
Male and postmenopausal female patients will be en-
rolled in this study. However, differences between the
two genders will not be investigated. The average sur-
vival time of the patients participating in this trial is
under 6 months. However, the follow-up period for the
patients as defined per protocol is up to 24 months. The
study treatment might confer clinical benefit and is
given first-line as an add-on to standard of care. Taking
further into account other factors, among them the mul-
tiple primary and secondary pharmacodynamic preclin-
ical studies, the risk-benefit analysis is assumed to have
a favorable result for the patient population selected.
The patient population and the study design were dis-
cussed in National Scientific Advice meetings with the
PEI (Langen, Germany) and the Medical Products
Agency (Uppsala, Sweden) and were considered ad-
equate to achieve the study objectives. The firstadministration of a gene transfer medicinal product can-
not be justified in healthy volunteers.
The starting dose consists of a solution containing 106
colony forming units (CFU) of VXM01 or placebo. This
VXM01 dose was chosen for safety reasons and is
assumed to be below the minimal effective dose to elicit
an immune response. For comparison, one dose of
TyphoralW, the licensed vaccine against typhoid fever,
contains 2x109 to 6x109CFU of Salmonella typhi Ty21a,
equivalent to approximately thousand times the VXM01
starting dose [22]. The dose will be escalated in factor-
of-ten logarithmic steps, which appears to be justified
for a live bacterial vaccine.
Complying with guidelines of first in human trials [23],
the patients of one dose group will be treated in cohorts.
The first administration of VXM01 in any dose group
will be given to one patient only accompanied by one
patient receiving placebo. The second cohort of each
dose group consists of two patients receiving VXM01
and one patient receiving placebo. This staggered admin-
istration with one front-runner, i.e. only one patient re-
ceiving VXM01 first, serves to mitigate the risks [23].
A third cohort of patients (three receiving VXM01 and
one receiving placebo) will be included in the 108, 109,
and 1010 dose groups. This approach minimizes expos-
ure to VXM01 doses assumed to be sub-therapeutic.
The third cohort and the first two cohorts of the next
higher treatment group may be treated in parallel based
on a clearly defined randomization strategy. This strat-
egy allows for recruitment of available patients and
avoids selection bias for patients treated in parallel in
the lower and higher dose group. In the 106 and 107
dose groups, a third cohort of patients will be included
only if one patient out of the initial three patients receiv-
ing VXM01 of the respective dose group experiences a
DLT and requires confirmation by a decision of the Data
Safety Monitoring Board (DSMB). The study design is
depicted in Figure 1.
The environmental risk inherent to an oral vaccine is
the potential of excretion to the environment and subse-
quent vaccination of people outside the target popula-
tion. All study patients will be confined in the study site
(KliPS) for the period during which vaccinations take
place plus three additional days. All feces of study
patients will be collected and incinerated. Body fluids
and feces samples will be investigated for VXM01 shed-
ding. As documented in the literature Ty21a, the bacter-
ial carrier of VXM01 was not excreted up to a dose of
109 cfu After administration of a dose of 1010 cfu of
Ty21a fecal excretion was observed until two days after
vaccination [24].
Hygienic precautions will be applied to protect study
personnel from accidental uptake. Study personnel will
be trained specifically for this aspect of the study.
Table 1 Eligibility Criteria
Inclusion Criteria
1 Written informed consent, signed and dated
2 Locally advanced, inoperable and stage IV pancreatic cancer
patients according to UICC based on diagnostic imaging using
computer-tomography (CT) or histological examinations
3 Male or post-menopausal female
4 Age ≥18 years
5 Chemotherapy naïve within 60 days before screening visit except
gemcitabine treatment
6 Karnofsky index >70
7 Life expectancy >3 months
8 Adequate renal, hepatic, and bone marrow function
9 Absolute neutrophil count >1500/μL
10 Hemoglobin >10 g/dL
11 Platelets >75000/μL
12 Prothrombin time and international normalized ratio (INR) <1.5
times upper limit of normal (ULN) (except under anticoagulant
treatment)
13 Aspartate aminotransferase <4 times ULN
14 Alanine aminotransferase <4 times ULN
15 Total bilirubin <3 times ULN
16 Creatinine clearance estimated according to Cockcroft-
Gault > 30 mL/min
17 Proteinuria <1 g protein on 24 h urine collection
Exclusion Criteria
1 State after pancreas resection (complete or partial)
2 Resectable disease
3 Drug trial participation within 60 days before screening visit
4 Other previous or current malignancy except basal or squamous
cell skin cancer, in situ cervical cancer, or any other cancer from
which the patient has been disease-free for <2 years
5 Prior vaccination with Ty21a
6 Cardiovascular disease defined as:
Uncontrolled hypertension (systolic blood pressure >160 mmHg or
diastolic blood pressure >100 mmHg)
Arterial thromboembolic event within 6 months before
randomization including:
- Myocardial infarction
- Unstable angina pectoris
- Cerebrovascular accident
- Transient ischemic attack
7 Congestive heart failure New York Heart Association grade III to IV
8 Serious ventricular arrhythmia requiring medication
9 Clinically significant peripheral artery disease > grade 2b according
to Fontaine
10 Hemoptysis within 6 months before randomization
11 Esophageal varices
12 Upper or lower gastrointestinal bleeding within 6 months before
randomization
Table 1 Eligibility Criteria (Continued)
13 Significant traumatic injury within 4 weeks before randomization
14 Non-healing wound, bone fracture or any history of
gastrointestinal ulcers within three years before inclusion, or
positive gastroscopy within 3 months before inclusion
15 Gastrointestinal fistula
16 Thrombolysis therapy within 4 weeks before randomization
17 Bowel obstruction within the last 30 days before screening visit
18 Liver cirrhosis≥ grade B according to Child-Pugh Score-
Classification
19 Presence of any acute or chronic systemic infection
20 Radiotherapy within 4 weeks before randomization
21 Major surgical procedures, or open biopsy within 4 weeks before
randomization
22 Fine needle aspiration within 7 days before randomization
23 Chronic concurrent therapy within 2 weeks before and during the
double-blind study period with:




- Any epidermal growth factor receptor inhibitor
- Chemotherapy except gemcitabine before Day 10
224 Multi-drug resistant gram-negative germ
25 Pregnancy
26 Lactation
227 Inability to comply with study and/or follow-up procedures
28 History of other disease, metabolic dysfunction, physical
examination finding, or clinical laboratory finding giving
reasonable suspicion of a disease or condition that contraindicates
the use of an investigational drug or that might affect the
interpretation of the study results or render the patient at high risk
for treatment complications
29 Women of childbearing potential
30 Any history of drug hypersensitivity
31 Any condition which results in an undue risk for the patient during
the study participation according to the investigator
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test negative for excretion of the vaccine after the last
administration of the study drug. In case a patient tests
positive for excretion after the last administration, an
antibiotic decontamination of the gastrointestinal tract
will be conducted before the patient is discharged. Ex-
cretion will be followed up until results are negative.
These measures appear to be justified and sufficient to
protect the environment and study personnel from ex-
posure to VXM01 until the shedding profile has been
elucidated.
VXM01 will be applied in parallel to the gemcitabine
background therapy as shown in Figure 2 (overall study
scheme). In brief, gemcitabine is given on days 1, 8, and
Figure 1 Dose escalating design.
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given four times on days 1, 3, 5, and 7, starting three
days after the last dose of gemcitabine. The double
blinded phase of the study will end 31 days after the last
patient has received the last administration.
Discussion
This study aims to find a safe and effective dose of the
experimental oral vaccine VXM01 targeting the human
VEGFR-2 for use during further investigation in a phase
II clinical trial. Despite years of failure, a first active im-
mune therapy, Dendreon’s Provenge, was efficacious in
prostate cancer, and as a consequence has been
approved by the FDA [25]. Several more tumor vaccines
are now in the midst or entering late-stage development
[26]. However, all these approaches are targeting so-
called tumor-associated antigens (TAA). For example,
vaccines targeting MUC-1 (stimuvax) and the TAA
Mage-A3 are currently under development in phase III
clinical trials [27,28].
VXM01 represents a novel strategy by targeting not a
tumor cell-resident antigen, but a tumor stroma-resident
antigen, overexpressed by non-malignant endothelial
cells of the tumor neovasculature. A Japanese group has
recently published a phase I study, implementing a sin-
gle VEGFR-2-derived peptide administered in weeklyintervals via the subcutaneous route of administration,
thus following a similar approach, but restricting it to a
certain HLA type [29].
By targeting genetically stable and easily accessible
endothelial cells, this product aims to overcome limita-
tions encountered previously by vaccines targeting tumor
cells directly, such as to tumor-cell heterogeneity,
MHC-loss, immunosupression on a cellular level and
tumor encapsulation as well as physiological barriers
such as the blood brain barrier. Furthermore, since the
therapeutic target is independent of the tumor type, the
vaccine may potentially be active against a variety of
different solid malignancies. The product represents a
patient-independent, “off-the-shelf” oral vaccine, which
can be stored and distributed to the clinical sites for use.
While anti-angiogenic therapy, either via small molecules
or via antibodies, has already been proven to be effect-
ive, our approach differs significantly by activating the
patient’s own immune system against tumor neovascula-
ture and is as such potentially creating a T-cell memory
effect that provides long-term efficacy. Studies with beva-
cizumab in colon and ovarian cancer suggest that contin-
ued anti-angiogenic pressure is required to maintain
beneficial treatment effects in the long term [30-32].
Should adverse events occur that resemble hypersensi-
tivity reactions mediated by histamine, leukotrienes, or
Figure 2 Overall Study Scheme.
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pressure instability, bronchospasm, and dyspnoea are
available. Treatment options in case of unwanted T-cell
derived autoaggression are derived from standard treat-
ment schemes in acute and chronic graft vs. host disease
applied after stem cell transplantation. Cyclosporin and
glucocorticoids are proposed as treatment options.
In the unlikely case of systemic Salmonella typhi
Ty21a type infection, appropriate antibiotic therapy with
fluoroquinolones including ciprofloxacin or ofloxacin is
recommended [33]. Bacterial infections of the gastro-
intestinal tract are to be treated with rifaximin.
For this phase I trial (advanced or stage IV pancreatic
cancer patients) a patient population with dismal prog-
nosis and the relatively gentle standard of care with re-
gard to immunosuppression was chosen. Co-regimes of
gemcitabine with tumor vaccination have even been
reported to be synergistic [34,35]. In addition, specific T-
cell activation can be measured in this patient setting
and may give an early indication of potential effective-
ness of the vaccine VXM01. By including a placebo con-
trol in the present trial, we will gain further knowledge
on specific safety issues related to the active vaccine vs.
the background treatment. In addition, the pooled pla-
cebo patients will serve as a sound comparator in orderto assess specific immune activation and other signs of
clinical efficacy. If and when moving into phase II, a dif-
ferent patient entity with a longer life expectancy can be
envisaged depending on the observed safety profile. Such
studies will also include tumor types that have shown to
be more susceptible to anti-angiogenic treatment.
We recognize the limitations inherent with a single
center study and hope to partially address any bias by
the introduction of the blinded placebo patients and an
independent unblinded DSMB, which is without direct
patient access. Further, the lack of a clear expectation
as to what constitutes a sufficient positive immune re-
action may be viewed as problematic. However, the
read-out allows for a proof of a successful specific im-
mune reaction. We have set predefined thresholds as to
the positivity of our immunological assays. As to how
far this can be correlated with dose and/or patient’s
response remains to be seen.
Conclusions
VXM01 has the potential to target a variety of tumor
types and to overcome multiple hurdles encountered by
other present cancer vaccine approaches. A tempting
vision is the possibility of combining our vaccine with a
multitude of other anti-cancer and immune-modulatory
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humans will allow so.
The results of the here presented study will guide us
to either modify our approach or to move forward into
the next steps of clinical development.
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